A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder

Satyam, Abhigyan; Singh, Prabhjot; Badjatia, Nitika; Seth, Amlesh; Sharma, Alpana

doi:10.1016/j.urolonc.2009.06.002

Cited by 42 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, Th2 is dominant in tumor environments, resulting in the inhibition of cellular immune responses. Even patients with bladder cancer are no exception, Th2 polarization occurs, and the shift from Th1 to Th2 cytokine production might facilitate tumor progression [36]. That is, the rescue from Th2 dominance to Th1 dominance is indispensable for achieving immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Nanoparticulation of BCG-CWS for application to bladder cancer therapy

Nakamura

Fukiage

Higuchi

et al. 2014

Journal of Controlled Release

View full text Add to dashboard Cite

The Mycobacterium bovis Bacille Calmett-Guerin cell wall skeleton (BCG-CWS) could be used to replace live BCG as a bladder cancer drug. However, because BCG-CWS is poorly soluble, has a strong-negative charge, very high molecular weight and heterogeneity in size of tens of μm, it cannot be used in such an application. We report herein on the development of a novel packaging method that permits BCG-CWS to be encapsulated into 166 nm-sized lipid particles. The BCG-CWS encapsulated nano particle (CWS-NP) has a high uniformity and can be easily dispersed. Thus, it has the potential for use as a packaging method that would advance the scope of applications of BCG-CWS as a bladder cancer drug. In a functional evaluation, CWS-NP was efficiently taken up by mouse bladder tumor cells (MBT-2) in vitro and inhibited tumor growth in mice bearing MBT-2 tumors. Moreover, intravesically administered CWS-NP showed significant antitumor effects in a rat model with in naturally developed bladder cancer. An enhancement in Th1 differentiation by CWS-NP was also confirmed in human T cells. In conclusion, CWS-NP represents a promising delivery system for BCG-CWS for clinical development as a potent bladder cancer drug.

show abstract

Section: Discussionmentioning

confidence: 99%

Nanoparticulation of BCG-CWS for application to bladder cancer therapy

Nakamura

Fukiage

Higuchi

et al. 2014

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Studies have revealed that patients with bladder cancer develop a Th2 dominant status with a deficient Th1 immune response. Increased levels of IL-10 and other Th2 cytokines (e.g., IL-4, IL-5 and IL-6), along with decreased levels of Th1 cytokines (e.g., IFN-γ and IL-2), have been observed in the serum of bladder cancer patients (Agarwal et al, 2010;Satyam et al, 2011). This circulating cytokine profile seems to correlate well with the grade and severity of bladder cancer.…”

Section: Introductionmentioning

confidence: 97%

Role of IL-10 in Urinary Bladder Carcinoma and Bacillus Calmette-Guerin Immunotherapy

P.¹

2012

American Journal of Immunology

View full text Add to dashboard Cite

Problem statement: Bladder cancer is a common urologic cancer and intravesical Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is the mainstay in the treatment of superficial bladder cancer. However, the current BCG therapy is not desirable with respect to its efficacy and side effects. Interleukin (IL)-10, a T helper type (Th) 2 cytokine, plays an important regulatory role in bladder cancer immunosurveillance and BCG immunotherapy. Therefore, blocking IL-10 activity could be beneficial for bladder cancer patients undergoing BCG therapy. Approach: Treatment with intravesical BCG in combination with systemic IL-10 monoclonal antibody (mAb) specific for IL-10 neutralization or IL-10 receptor (IL-10R) blockage has been evaluated in preclinical bladder cancer models. Results: Addition of anti-IL-10 neutralizing mAb or anti-IL-10R1 mAb enhances BCG induction of Th1 immune responses and anti-bladder cancer immunity. Conclusion/Recommendations: BCG immunotherapy of bladder cancer can be enhanced by addition of IL-10 blocking mAb. Future studies should aim to explore the mechanisms underlying the induction of enhanced antitumor immunity by BCG combination therapy and develop therapeutic regimens for clinical evaluation of the safety and efficacy of BCG combination therapy.

show abstract

“…Este último permite às células neoplásicas criarem um ambiente de tolerância, levando ao crescimento e à malignidade tumoral (SATYAM et al, 2011;DUNN et al, 2004). A malignidade dos tumores mamários pode estar relacionada com a resposta inflamatória induzida por linfócitos e outras células inflamatórias infiltradas no sítio de crescimento tumoral, tais como os macrófagos regulatórios M2 (REOME et al, 2004).…”

Section: Introductionunclassified

“…+ (HORIUCHI et al, 2007), que se subdividem em Th1 e Th2, com um perfil de citocinas específicas, que levam a uma resposta imune celular (Th1) ou humoral (Th2) (REED, 1995;YAMAZAKI et al, 2002;HORIUCHI, et al, 2007). O desequilíbrio para um perfil Th2 está relacionado com o desenvolvimento de diversos tumores, pela supressão da resposta antitumoral das células Th1 (SATYAM et al, 2011).…”

Section: Introductionunclassified

“…O desequilíbrio para um perfil Th2 está relacionado com o desenvolvimento de diversos tumores, pela supressão da resposta antitumoral das células Th1 (SATYAM et al, 2011). A IL-10 está envolvida na inibição da ativação dos macrófagos, limitando a produção de IL-1, IL-6, TNF-α, bem como, a ativação antígeno-específico dos linfócitos T, pela regulação negativa das células apresentadoras de antígenos e inibição da expansão de células T pela inibição da produção de IL-2.…”

Section: Introductionunclassified

See 1 more Smart Citation

A Interleucina-10 E Seu Papel Nos Carcinomas Mamários Caninos

Garrido

Castanheira

Rosolem

et al. 2015

Ars Vet

View full text Add to dashboard Cite

RESUMOA interleucina-10 (IL-10) pode estar relacionada aos mecanismos de evasão tumoral, promovendo a progressão do tumor. O objetivo deste trabalho foi determinar a relação entre a secreção de IL-10, o tipo histológico tumoral e a intensidade da reação inflamatória no sítio tumoral, comparando a imunomarcação de IL-10, por imuno-histoquímica, entre os grupos de amostras de carcinomas mamários e de tecido mamário hígido em cadelas. No presente estudo foi verificado um aumento significativo no número de células imunomarcadas no grupo carcinoma e, também, uma associação entre a intensidade da inflamação, a secreção de IL-10. Com este estudo pode-se concluir que o aumento na secreção de IL-10 influenciado pelo carcinoma mamário pode criar um microambiente favorável para a progressão do tumor, possivelmente pela supressão de citocinas pró-inflamatórias e pela proliferação de subtipos de linfócitos com efeito imunossupressor, como os linfócitos T regulatórios. PALAVRAS-CHAVE:Câncer. Citocinas. Evasão tumoral. Reação inflamatória. SUMMARYThe Interleukin-10 may related to tumor evasion mechanisms by promoting tumor progression. The objective of this study was to determine the relationship between IL-10 secretion, histologic tumor type and the intensity of the inflammatory reaction in the tumor site, comparing immunostaining of IL-10, by immunohistochemistry, between groups of carcinoma breast samples and breast tissue in healthy bitches. The present study found a significant increase in the number of immunostained cells in the carcioma group and an association between the intensity of inflammation and IL-10 secretion. With this study, we can concluded that the increase in IL-10, affected by mammary carcinoma secretion, can create a microenvironment advantageous to tumor progression, possibly due to the suppression of proinflammatory cytokines and the proliferation of subtype of lymphocyte with immunosuppressive effect, like regulatory T lymphocytes.

show abstract

A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder

Cited by 42 publications

References 34 publications

Nanoparticulation of BCG-CWS for application to bladder cancer therapy

Nanoparticulation of BCG-CWS for application to bladder cancer therapy

Role of IL-10 in Urinary Bladder Carcinoma and Bacillus Calmette-Guerin Immunotherapy

A Interleucina-10 E Seu Papel Nos Carcinomas Mamários Caninos

Contact Info

Product

Resources

About